Cargando…

Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)

BACKGROUND: Secukinumab is a human monoclonal antibody immunoglobulin that neutralises interleukin (IL)-17A, and as such, is effective in the treatment of psoriasis. However, as IL-17A is essential in protection against fungal infections, patients treated with this drug may develop candidiasis. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Picciani, Bruna Lavinas Sayed, Dziedzic, Arkadiusz, Werneck, Juliana Tristão, Marinho, Marcello Alves, Dick, Thaylla Núñez Amin, Quintanilha, Nara Regina, Dias, Eliane Pedra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186152/ https://www.ncbi.nlm.nih.gov/pubmed/34103043 http://dx.doi.org/10.1186/s12903-021-01653-6

Ejemplares similares

Oral Lesions as the Primary Manifestations of Behçet’s Disease: The Importance of Interdisciplinary Diagnostics—A Case Report
por: Soares, Alvaro Cavalheiro, et al.
Publicado: (2023)

Abrupt Development of Esophageal Candidiasis after Secukinumab Treatment in a Psoriatic Patient
por: Kang, Hyun Jin, et al.
Publicado: (2021)

Evaluation of the Th17 pathway in psoriasis and geographic tongue()()
por: Picciani, Bruna Lavinas Sayed, et al.
Publicado: (2019)

Dental Treatment under General Anesthesia in Patients with Special Needs Provided by Private and Public Healthcare Services—A Retrospective, Comparative Study
por: Marinho, Marcello Alves, et al.
Publicado: (2022)

Applicability of the Geographic Tongue Area and Severity Index among Healthcare Professionals: A Cross-Sectional Clinical Validation of a Newly Developed Geographic Tongue Scoring System
por: Picciani, Bruna Lavinas Sayed, et al.
Publicado: (2021)

Preliminary Assessment of the Quality of Life and Daily Burden of Caregivers of Persons with Special Needs: A Questionnaire-Based, Cross-Sectional Survey
por: Cardoso, Andréa Lanzillotti, et al.
Publicado: (2023)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Contribution of benzodiazepines in dental care of patients with special needs
por: Picciani, Bruna-Lavinas-Sayed, et al.
Publicado: (2019)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Changes in metabolic parameters in psoriatic patients treated with secukinumab
por: Wang, Hsuan Ning, et al.
Publicado: (2020)

Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis
por: Kirby, Colm, et al.
Publicado: (2021)

Gingival and alveolar mucosal reactive hyperplastic lesions: a retrospective clinical and histological study of 996 cases
por: Baesso, Rafaela Carriço Porto, et al.
Publicado: (2023)

Geographic tongue and psoriasis: clinical, histopathological, immunohistochemical and genetic correlation - a literature review
por: Picciani, Bruna Lavinas Sayed, et al.
Publicado: (2016)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Are Special Care Dentistry Services Prepared for a Global Disruption in Healthcare? A Call for a Wider Promotion of Dental Conscious Sedation Training
por: Dziedzic, Arkadiusz, et al.
Publicado: (2020)

Regression of Major Recurrent Aphthous Ulcerations Using a Combination of Intralesional Corticosteroids and Levamisole: A Case Report
por: Picciani, Bruna Lavinas Sayed, et al.
Publicado: (2010)

Prevalence and heritability of psoriasis and benign migratory glossitis in one Brazilian population
por: Jorge, Maria Augusta, et al.
Publicado: (2017)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis
por: CHELLI, Clara, et al.
Publicado: (2020)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
por: Schweikert, Bernd, et al.
Publicado: (2020)

Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study
por: Damiani, Giovanni, et al.
Publicado: (2019)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2020)

New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?
por: Obeidat, Adham E, et al.
Publicado: (2021)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Successful treatment with secukinumab in an HIV‐positive psoriatic patient after failure of apremilast
por: Romita, Paolo, et al.
Publicado: (2022)

Recurrent Esophageal Candidiasis Induced by Secukinumab: Discrepancy between Clinical Trials and Real-World Data
por: Seo, Ji-In, et al.
Publicado: (2023)

Oral lichen planus: study of 21 cases
por: Werneck, Juliana Tristão, et al.
Publicado: (2015)

Secukinumab on Refractory Lupus Nephritis
por: Costa, Rita, et al.
Publicado: (2021)

Intraoral soft tissue lipomas: clinicopathological features from 91 cases diagnosed in a single Oral Pathology service
por: Pires, Fábio Ramôa, et al.
Publicado: (2021)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
por: Coates, Laura C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1qi5eu30ctiutuaoqho484ur2v